William L Carroll Selected Research

pegaspargase (Oncaspar)

10/2021	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
1/2021	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
10/2020	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
10/2020	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
1/2019	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.
10/2018	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
1/2016	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
7/2015	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
7/2013	Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William L Carroll Research Topics

Disease

106	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 01/2003
29	Neoplasms (Cancer) 01/2022 - 01/2003
25	Leukemia 01/2022 - 10/2002
14	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 08/2006
12	Residual Neoplasm 04/2021 - 01/2009
7	Philadelphia Chromosome 01/2018 - 06/2009
5	Infections 01/2021 - 08/2008
4	Hypersensitivity (Allergy) 01/2021 - 07/2013
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2019 - 01/2007
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2012
3	Pancreatitis 01/2018 - 07/2013
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 02/2015
2	Osteonecrosis (Kienbock's Disease) 10/2016 - 10/2015
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2016 - 01/2007
2	Glucocorticoid Receptor Deficiency 06/2015 - 07/2014
2	Lymphoma (Lymphomas) 08/2014 - 08/2014
2	Hemorrhage 08/2014 - 07/2013
2	Neuroblastoma 11/2004 - 08/2003
1	Severe Acute Respiratory Syndrome 01/2021
1	Central Nervous System Diseases (CNS Diseases) 10/2020
1	Necrosis 03/2020
1	Glycogen Storage Disease Type VI (Glycogenosis Type VI) 03/2020
1	B-Cell Leukemia (Leukemia, B Cell) 01/2020
1	Bites and Stings (Sting) 10/2019
1	Glucosephosphate Dehydrogenase Deficiency 01/2019

Drug/Important Bio-Agent (IBA)

13	Biological ProductsIBA 04/2021 - 10/2002
9	pegaspargase (Oncaspar)FDA Link 10/2021 - 07/2013
8	Asparaginase (Elspar)FDA Link 01/2021 - 07/2013
8	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 07/2011
8	Pharmaceutical PreparationsIBA 01/2020 - 04/2005
7	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2006
6	Proteins (Proteins, Gene)FDA Link 06/2021 - 09/2002
6	Phosphotransferases (Kinase)IBA 01/2017 - 04/2009
5	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 01/2019 - 06/2012
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 10/2016
4	nelarabine (506U78)FDA Link 10/2020 - 08/2012
4	GlucocorticoidsIBA 01/2018 - 06/2015
3	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 02/2015
3	Prednisone (Sone)FDA LinkGeneric 01/2020 - 08/2012
3	Monoclonal AntibodiesIBA 01/2018 - 08/2008
3	Cytokine Receptors (Cytokine Receptor)IBA 01/2017 - 07/2010
3	RNA (Ribonucleic Acid)IBA 07/2015 - 03/2013
2	ChromatinIBA 06/2021 - 07/2014
2	lestaurtinibIBA 05/2021 - 01/2021
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 08/2014
2	AntigensIBA 01/2021 - 10/2019
2	Leucovorin (Folinic Acid)FDA Link 10/2020 - 10/2018
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2019 - 08/2017
2	2-mercaptopurineIBA 10/2019 - 01/2018
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019 - 01/2012
2	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 12/2011
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 12/2011
2	Clofarabine (Clolar)FDA Link 01/2018 - 12/2011
2	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 11/2009
2	Transcription Factors (Transcription Factor)IBA 08/2017 - 09/2014
2	Thioguanine (Tioguanine)FDA Link 05/2017 - 06/2015
2	NucleotidesIBA 05/2017 - 06/2015
2	epratuzumabIBA 07/2015 - 08/2008
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 06/2015 - 07/2014
2	Anaplastic Lymphoma KinaseIBA 01/2015 - 09/2002
2	Messenger RNA (mRNA)IBA 08/2014 - 04/2012
2	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 06/2009
2	Histone Deacetylase InhibitorsIBA 05/2012 - 04/2009
2	Janus KinasesIBA 09/2011 - 07/2010
2	ProteomeIBA 01/2007 - 05/2006
1	Mitogen-Activated Protein KinasesIBA 10/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2022
1	ribociclibIBA 01/2022
1	Cytotoxins (Cytolysins)IBA 01/2022
1	palbociclibIBA 01/2022
1	Cyclin D3IBA 01/2022
1	Cyclin DIBA 01/2022
1	Drug CombinationsIBA 01/2022
1	Antigen Receptors (Antigen Receptor)IBA 04/2021
1	HLA-DQB1 antigen (HLA DQB1)IBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	AntimetabolitesIBA 01/2020
1	IntegrinsIBA 01/2020
1	ElementsIBA 12/2019
1	Immune Checkpoint InhibitorsIBA 10/2019
1	Chimeric Antigen ReceptorsIBA 10/2019
1	Essential Amino AcidsIBA 01/2019
1	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 01/2019
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2019
1	Bortezomib (Velcade)FDA Link 01/2019
1	AsparagineIBA 01/2019
1	AnthracyclinesIBA 01/2019
1	methylervineIBA 10/2018
1	prednylidene (Pred)IBA 01/2018
1	purine 5'-nucleotidaseIBA 01/2018

Therapy/Procedure

55	Therapeutics 12/2021 - 01/2003
30	Drug Therapy (Chemotherapy) 01/2022 - 06/2006
3	Hematopoietic Stem Cell Transplantation 01/2019 - 04/2009
3	Cranial Irradiation 10/2018 - 02/2016
3	Remission Induction 01/2017 - 01/2009
3	Precision Medicine 02/2016 - 08/2014
2	Immunotherapy 10/2020 - 01/2018
1	Radiotherapy 12/2021
1	Neoadjuvant Therapy 03/2020
1	Induction Chemotherapy 01/2018